Finding new tricks for old drugs: An efficient route for public-sector drug discovery

Nature Reviews Drug Discovery

Volumn 4, Issue 12, 2005, Pages 1005-1014

  O'Connor, Kerry A ^a   Roth, Bryan L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ANTIBIOTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA LACTAM; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEPHALOSPORIN; CHLORPROMAZINE; CLOZAPINE; CYCLOOXYGENASE 2 INHIBITOR; CYPROHEPTADINE; DIHYDROERGOTAMINE; FENFLURAMINE; FLUCONAZOLE; FLUPHENAZINE; GLUTAMATE TRANSPORTER; MIRTAZAPINE; NATALIZUMAB; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORFENFLURAMINE; PENICILLIN G; PERGOLIDE; PHENTERMINE; ROFECOXIB; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; ANTIINFECTIVE AGENT; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIMICROBIAL ACTIVITY; CARDIOVASCULAR DISEASE; CELL INTERACTION; CLINICAL TRIAL; CROHN DISEASE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TOLERANCE; DRUG WITHDRAWAL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; JC VIRUS; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; VIRUS INFECTION; WASTING SYNDROME; DRUG DESIGN; DRUG THERAPY; ECONOMICS; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PHARMACEUTICS; PRODUCTIVITY;

ANTI-BACTERIAL AGENTS; ANTIPSYCHOTIC AGENTS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY; EFFICIENCY; EFFICIENCY, ORGANIZATIONAL; FENFLURAMINE; HUMANS; NEUROPROTECTIVE AGENTS; PHENTERMINE; PUBLIC SECTOR; TECHNOLOGY, PHARMACEUTICAL;

EID: 33644668387     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1900     Document Type: Review

References (51)

1. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431, 931-945 (2004).
2. Zerhouni, E. Medicine. The NIH Roadmap. Science 302, 63-72 (2003).
3. Austin, C. P., Brady, L. S., Insel, T. R. & Collins, F. S. NIH Molecular Libraries Initiative. Science 306, 1138-1139 (2004).
4. Duyk, G. Attrition and translation. Science 302, 603-605 (2003).
5. Couzin, J. Molecular medicine. NIH dives into drug discovery Science 302, 218-221 (2003).
6. Strausberg, R. L. & Schreiber, S. L. From knowing to controlling: A path from genomics to drugs using small molecule probes. Science 300, 294-295 (2003).
7. Rawlins, M. D. Cutting the cost of drug development? Nature Rev. Drug Discov. 3, 360-364 (2004).
8. Haggarty, S. J., Clemons, P. A. & Schreiber, S. L. Chemical genomic profiling of biological networks using graph theory and combinations of small molecule perturbations. J. Am. Chem. Soc. 125, 10543-10545 (2003).
9. Armbruster, B. N. & Roth, B. L. Mining the receptorome. J. Biol. Chem. 280, 5129-5132 (2005).
10. Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nature Rev. Drug Discov 3, 353-359 (2004).
11. Coito, C., Diamond, D. L., Neddermann, P., Korth, M. J. & Katze, M. G. High-throughput screening of the yeast kinome: Identification of human serine/threonine protein kinases that phosphorylate the hepatitis C virus NS5A protein. J. Virol. 78, 3502-3513 (2004).
12. Johnson, S. A. & Hunter, T. Kinomics: Methods for deciphering the kinome. Nature Methods 2, 17-25 (2005).
13. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
14. Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727-730 (2002).
15. Ashburn, T. T. & Thor, K. B. Drug repositioning: Identifying and developing new uses for existing drugs. Nature Rev. Drug Discov. 3, 673-683 (2004).
16. Keith, C. T., Borisy A. A. & Stockwell, B. R. Multicomponent therapeutics for networked systems. Nature Rev. Drug Discov. 4, 71-78 (2005).
17. Pharmaceutical Researcher Manufacturers of America Pharmaceutical Industry Profile 2005 [online], (2005).
18. McCaig, L. F., Besser, R. E. & Hughes, J. M. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerging Infect. Dis. 9, 432-437 (2003).
19. Rothstein, J. D. et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433, 73-77 (2005).
20. Rothstein, J. D. et al. Knockout of glutamate transpoters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16, 675-686 (1996).
21. Maragakis, N. J., Dykes-Hoberg, M. & Rothstein, J. D. Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann. Neurol. 55, 469-477 (2004).
22. Beghi, E., Bendotti, C. & Mennini, T. Merits of a new drug trial for ALS? Science 308, 632-633; author reply 632-633 (2005).
23. Couratier, P., Vallat, J. M., Merle, L., Preux, P. M. & Hugon, J. Report of six sporadic cases of ALS patients receiving ceftriaxone. Therapie 49, 146 (1994).
24. Carelli, V., Liguori, R., Cordivari, C., Bianchedi, G. & Montagna, P. Ceftriaxone is ineffective in ALS. Ital. J. Neurol. Sci. 15, 66 (1994).
25. Koralnik, I. J. New insights into progressive multifocal leukoencephalopathy. Curr. Opin. Neurol. 17, 365-370 (2004).
26. Schreiner, B., Kieseier, B. C., Hartung, H. P., Hohlfeld, R. & Wiendl, H. Blocking adhesion molecules with natalizumab in multiple sclerosis. Nervenarzt 76, 999-1005 (2005).
27. Imperato, A. K., Bingham, C. O. & Abramson, S. B. Overview of benefit/ risk of biological agents. Clin. Exp. Rheumatol. 22, S108-S114 (2004).
28. Elphick, G. F. et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306, 1380-1383 (2004).
29. 2A receptors during endocytosis. J. Biol. Chem. 276, 8269-8277 (2001).
30. Summerbell, C. D., Youle, M., McDonald, V., Catalan, J. & Gazzard, B. G. Megestrol acetate versus cyproheptadine in the treatment of weight loss associated with HIV infection. Int. J. STD AIDS 3, 278-280 (1992).
31. Couzin, J. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 306, 384-385 (2004).
32. Connolly, H. M. et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337, 581-688 (1997).
33. Devereux, R. B. Appetite suppressants and valvular heart disease. N. Engl. J. Med. 339, 765-766 (1998).
34. 2B, receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836-2841 (2000).
35. Setola, V. et al. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 63, 1223-1229 (2003).
36. 2B receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57, 75-81 (2000).
37. Launay J. M. et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nature Med. 8, 1129-1135 (2002).
38. 2, receptor subtypes. J. Pharmacol. Exp. Ther. 303, 815-822 (2002).
39. Flowers, C. M., Racoosin, J. A., Lu, S. L. & Beitz, J. G. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin. Proc. 78, 730-731 (2003).
40. Van Camp, G. et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363, 1179-1183 (2004).
41. Horvath, J. et al. Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. Mov. Disord. 19, 656-662 (2004).
42. Clineschmidt, B. V., Hanson, H. M., Pflueger, A. B. & McGuffin, J. C. Anorexigenic and ancillary actions of MK-212 (6-chloro-2-(1-piperazinyl)-pyrazine; CPP). Psychopharmacology (Berl.) 55, 27-33 (1977).
43. Dourish, C. T. Multiple serotonin receptors: Opportunities for new treatments for obesity? Obes. Res. 3, S449-S462 (1995).
44. 2C, receptor mutant mice. Psychopharmacology (Berl.) 143, 309-314 (1999).
45. 2 family serotonin receptors reveal novel strategies for therapeutic target development. Exp. Opin. Ther. Targets 5, 685-695 (2001).
46. Combs, C. K., Bates, P., Karlo, J. C. & Landreth, G. E. Regulation of β-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem. Int. 39, 449-457 (2001).
47. Yen, Q. et al. Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23, 7504-7509 (2003).
48. Kukar, T. et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production. Nature Med. 11, 545-550 (2005).
49. Glaser, V. Immune Control pursues seotonin antagonists. Genet. Eng. News 24 [online], (2004).
50. 1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl.) 178, 451-460 (2005).
51. Eash, S. et al. Differential distribution of the JC virus receptor-type sialic acid in normal human tissues. Am. J. Pathol. 164, 419-428 (2004).